[1] Kiernan MC, Vucic S, Talbot K, McDermott CJ, Hardiman O, Shefner JM, Al-Chalabi A, Huynh W, Cudkowicz M, Talman P, Van den Berg LH, Dharmadasa T, Wicks P, Reilly C, Turner MR. Improving clinical trial outcomes in amyotrophic lateral sclerosis[J]. Nat Rev Neurol, 2021, 17:104-118. [2] Chiò A, Calvo A, Moglia C, Mazzini L, Mora G; PARALS Study Group. Phenotypic heterogeneity of amyotrophic lateral sclerosis:a population based study[J]. J Neurol Neurosurg Psychiatry, 2011, 82:740-746. [3] Huynh W, Ahmed R, Mahoney CJ, Nguyen C, Tu S, Caga J, Loh P, Lin CS, Kiernan MC. The impact of cognitive and behavioral impairment in amyotrophic lateral sclerosis[J]. Expert Rev Neurother, 2020, 20:281-293. [4] Beeldman E, Govaarts R, de Visser M, Klein Twennaar M, van der Kooi AJ, van den Berg LH, Veldink JH, Pijnenburg YAL, de Haan RJ, Schmand BA, Raaphorst J. Progression of cognitive and behavioural impairment in early amyotrophic lateral sclerosis[J]. J Neurol Neurosurg Psychiatry, 2020, 91:779-780. [5] Consonni M, Dalla Bella E, Bersano E, Lauria G. Cognitive and behavioural impairment in amyotrophic lateral sclerosis. A landmark of the disease:a mini review of longitudinal studies[J]? Neurosci Lett, 2021, 754:135898. [6] Brooks BR, Miller RG, Swash M, Munsat TL; World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited:revised criteria for the diagnosis of amyotrophic lateral sclerosis[J]. Amyotroph Lateral Scler Other Motor Neuron Disord, 2000, 1:293-299. [7] Shen D, Hou B, Xu Y, Cui B, Peng P, Li X, Tai H, Zhang K, Liu S, Fu H, Gao J, Liu M, Feng F, Cui L. Brain structural and perfusion signature of amyotrophic lateral sclerosis with varying levels of cognitive deficit[J]. Front Neurol, 2018, 9:364. [8] Chen ZY, Liu MQ, Ma L. Gray matter volume changes over the whole brain in the bulbar-and spinal-onset amyotrophic lateral sclerosis:a voxel-based morphometry study[J]. Chin Med Sci J, 2018, 33:20-28. [9] Mezzapesa DM, D'Errico E, Tortelli R, Distaso E, Cortese R, Tursi M, Federico F, Zoccolella S, Logroscino G, Dicuonzo F, Simone IL. Cortical thinning and clinical heterogeneity in amyotrophic lateral sclerosis[J]. PLoS One, 2013, 8:e80748. [10] Kim HJ, de Leon M, Wang X, Kim HY, Lee YJ, Kim YH, Kim SH. Relationship between clinical parameters and brain structure in sporadic amyotrophic lateral sclerosis patients according to onset type:a voxel-based morphometric study[J]. PLoS One, 2017, 12:e0168424. [11] Trojsi F, Di Nardo F, Santangelo G, Siciliano M, Femiano C, Passaniti C, Caiazzo G, Fratello M, Cirillo M, Monsurrò MR, Esposito F, Tedeschi G. Resting state fMRI correlates of theory of mind impairment in amyotrophic lateral sclerosis[J]. Cortex, 2017, 97:1-16. [12] Schuster C, Kasper E, Machts J, Bittner D, Kaufmann J, Benecke R, Teipel S, Vielhaber S, Prudlo J. Focal thinning of the motor cortex mirrors clinical features of amyotrophic lateral sclerosis and their phenotypes:a neuroimaging study[J]. J Neurol, 2013, 260:2856-2864. [13] Bede P, Bokde A, Elamin M, Byrne S, McLaughlin RL, Jordan N, Hampel H, Gallagher L, Lynch C, Fagan AJ, Pender N, Hardiman O. Grey matter correlates of clinical variables in amyotrophic lateral sclerosis (ALS):a neuroimaging study of ALS motor phenotype heterogeneity and cortical focality[J]. J Neurol Neurosurg Psychiatry, 2013, 84:766-773. [14] Ravits JM, La Spada AR. ALS motor phenotype heterogeneity, focality, and spread:deconstructing motor neuron degeneration[J]. Neurology, 2009, 73:805-811. [15] Nitert AD, Tan HH, Walhout R, Knijnenburg NL, van Es MA, Veldink JH, Hendrikse J, Westeneng HJ, van den Berg LH. Sensitivity of brain MRI and neurological examination for detection of upper motor neurone degeneration in amyotrophic lateral sclerosis[J]. J Neurol Neurosurg Psychiatry, 2022, 93:82-92. [16] Ishaque A, Ta D, Khan M, Zinman L, Korngut L, Genge A, Dionne A, Briemberg H, Luk C, Yang YH, Beaulieu C, Emery D, Eurich DT, Frayne R, Graham S, Wilman A, Dupré N, Kalra S. Distinct patterns of progressive gray and white matter degeneration in amyotrophic lateral sclerosis[J]. Hum Brain Mapp, 2022, 43:1519-1534. [17] van der Burgh HK, Westeneng HJ, Walhout R, van Veenhuijzen K, Tan HHG, Meier JM, Bakker LA, Hendrikse J, van Es MA, Veldink JH, van den Heuvel MP, van den Berg LH. Multimodal longitudinal study of structural brain involvement in amyotrophic lateral sclerosis[J]. Neurology, 2020, 94:e2592-2604. [18] Dreger M, Steinbach R, Otto M, Turner MR, Grosskreutz J. Cerebrospinal fluid biomarkers of disease activity and progression in amyotrophic lateral sclerosis[J]. J Neurol Neurosurg Psychiatry, 2022, 93:422-435. [19] Xu X, Shen D, Gao Y, Zhou Q, Ni Y, Meng H, Shi H, Le W, Chen S, Chen S. A perspective on therapies for amyotrophic lateral sclerosis:can disease progression be curbed[J]? Transl Neurodegener, 2021, 10:29. |